TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28151459
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day Nigella sativa (NS-1)
Study: 28151459
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day Nigella sativa (NS-2)
Study: 12518490
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction (advanced-design manual toothbrush)
Study: 12518490
Drug: Oral-B 40
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B 40 Indicator (flat-trimmed toothbrush)
Study: 1958449
Drug: RG 12525
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12525 800 mg
Study: 28464041
Drug: PopART intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PopART intervention (universal testing and treatment)
Study: 10943876
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral methotrexate (MTX) 15 mg/m2 (increased to 20 mg/m2 after 2 months)
Study: 1736617
Drug: Dofetilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (1 of 2 dose levels)
Study: 1736617
Drug: Dofetilide (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (high-dose level)
Study: 31564933
Drug: PEDYPHAR ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEDYPHAR ointment
Study: 31564933
Drug: Panthenol ointment
Normalized name: Panthenol
DrugBank: Panthenol (DB11204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panthenol ointment (control)
Study: 30594223
Drug: Incentive Scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive Scheme with motivational interviewing; gift vouchers of US$5.6 for VL < 20 copies/mL at 12 weeks, US$2.8 for VL suppression for the next 3 months, US$5.6 for VL < 20 copies/mL at 1 year.
Study: 19917571
Drug: PI-88 in
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI-88 in combination with docetaxel (75 mg/m2 every three weeks)
Study: 10229064
Drug: Lorazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (6 mg/day)
Study: 8912562
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (0.5 to 2 micrograms daily)
Study: 1819620
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g i.v. of imipenem‐cilastatin at induction of anesthesia
Study: 1819620
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g i.v.) plus metronidazole (0.5 g i.v.) at the time of anesthesia and two other administrations of the combined antibiotics (cefuroxime 0.75 g plus metronidazole 0.5 g i.v.) every 8 hours
Study: 6698566
Drug: Meptazinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (200 mg 3 hourly for 4 doses)
Study: 6698566
Drug: Meptazinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (200 mg 3 hourly for 4 doses) + Ethanol (0.8 g/kg)
Study: 26179814
Drug: Standard pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmaceutical care (control)
Study: 8758193
Drug: Best conventional
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best conventional therapy
Study: 30092411
Drug: Monotherapy (amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od)
Study: 30092411
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od)
Study: 22907609
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg kg(‐1) bolus during induction, followed by 2 mg kg(‐1) h(‐1) intraoperative infusion and 1.3 mg kg(‐1) h(‐1) for 24 h postoperatively)
Study: 12572373
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of methotrexate (MTX), sulfasalazine (SSZ) and Fengshi No. 1 (FS1)
Study: 9440376
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 12 mg.kg‐1.d‐1
Study: 9440376
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 28 mg.kg‐1.d‐1
Study: 8595517
Drug: IL-1ra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra (100 mg bolus followed by 2.0 mg/kg/h i.v. for 72 h)
Study: 227571
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CCNA, methotrexate, and adriamycin in epidermoid carcinoma
Study: 227571
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CCNU, cyclophosphamide, and methotrexate in adenocarcinoma
Study: 227571
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide and adriamycin
Study: 227571
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CCNU, procarbazine, and 5-fluorouracil
Study: 27461168
Drug: Sorghum bicolor
Normalized name: SORGHUM BICOLOR WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorghum bicolor extract (500 mg/d) + folic acid (5 mg/d) + iron (200 mg three times daily)
Study: 27461168
Drug: Routine hematinics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hematinics (folic acid 5 mg/d and iron 200 mg three times daily)
Study: 23426033
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (600 mg/d)
Study: 21768541
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplementation (40 g/d for 8 weeks)
Study: 21768541
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein supplementation (40 g/d for 8 weeks)
Study: 19961750
Drug: Mini-screw implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-screw implants
Study: 10741813
Drug: Bupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (5 ml of 0.25% bupivacaine at each incisional area, total of 20 ml)
Study: 10741813
Drug: Control (physiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (physiologic saline solution, total of 20 ml)
Study: 1586367
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy (exposure in vivo and response prevention)
Study: 1586367
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy followed by cognitive therapy
Study: 1586367
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy followed by behavioural therapy
Study: 24338242
Drug: Anesthesiologist-administered sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesiologist-administered sedation
Study: 24338242
Drug: Nurse-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered propofol sedation (NAPS) or endoscopist-directed sedation (EDS)
Study: 23240152
Drug: Melatonin (melaxen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (melaxen, 1.5 mg, 2 weeks)
Study: 20479445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received nonsteroidal anti-inflammatory drugs, orthoses, and corticosteroid injections if needed)
Study: 15230045
Drug: Trimetazidine 60
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 60 mg/day for 4 weeks
Study: 11382726
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa antagonist therapy with >/=95% platelet inhibition at 10 minutes after therapy initiation
Study: 11382726
Drug: Platelet function
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet function inhibition <70% at 8 hours after therapy initiation
Study: 11382726
Drug: Platelet function
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet function inhibition >/=95% at 10 minutes after therapy initiation
Study: 8102894
Drug: Cefotaxime (Claforan)
Normalized name: cefotaxime Injection [Claforan]
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (Claforan) 2 g intravenously at induction and 3 and 9 hours later (n = 280)
Study: 8102894
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g plus metronidazole (Flagyl) 1.5 g intravenously at induction (n = 287)
Study: 3111953
Drug: FOY (injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOY (injectable synthetic protease inhibitor)
Study: 18467725
Drug: Initial adjuvant
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial adjuvant treatment with fluorouracil (FU)-based therapy
Study: 8978020
Drug: Live varicella
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live varicella zoster virus (VZV) vaccine
Study: 8978020
Drug: Killed varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed varicella zoster virus (VZV) vaccine
Study: 6152344
Drug: Cholecystokinin-octapeptide (CCK-8)
Normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholecystokinin-octapeptide (CCK-8) 10 micrograms weekly intravenous injections
Study: 21137167
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Urovaxom and Luivac combined with small doses of fluorochinolones over 12 months
Study: 21137167
Drug: Long-term chemoprophylaxis
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term chemoprophylaxis with small doses of fluorochinolones
Study: 15226323
Drug: Bicalutamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (150 mg by mouth daily)
Study: 3264710
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg four times daily; 17 doses)
Study: 3264710
Drug: Indomethacin BP
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin BP (50 mg three times daily; 13 doses)
Study: 3264710
Drug: Indocid‐R (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indocid‐R (75 mg twice daily; 9 doses)
Study: 3264710
Drug: Indomethacin Continus
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin Continus (75 mg twice daily; 9 doses)
Study: 23514770
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplementation (MMS) with 5 mg of iron (ferrous sulfate) for 5 months
Study: 20470276
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (50 mg) with N-acetylcysteine
Study: 20470276
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (100 mg)
Study: 20470276
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (50 mg)
Study: 14736075
Drug: Inosiplex (Isoprinosine)
Normalized name: Inosiplex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosiplex (Isoprinosine) 100 mg/kg/day to a maximum of 3 g/day, taken orally in three divided doses for 6 months
Study: 14736075
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of inosiplex and intraventricular interferon‐alpha2b (Intron A), starting with 100,000 U/m2 and escalating to 1,000,000 U/m2 over 5 inpatient days, then 1,000,000 U/m2 twice a week for 6 months
Study: 10425809
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (25 mg/kg)
Study: 2272191
Drug: Cronassial (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cronassial (100 mg in 2 ml buffered solution)
Study: 6250769
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of Acyclovir (9‐(2‐hydroxyethoxymethyl)guanine)
Study: 21860339
Drug: Nevirapine treatment
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine treatment in patients with different genotypes
Study: 21860339
Drug: Nevirapine treatment
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine treatment in patients with CYP2B6 516G>T polymorphism
Study: 21860339
Drug: Nevirapine treatment
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine treatment in patients with CYP2C19 8403AA genotype
Study: 19387646
Drug: Methotrexate plus
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate plus TNF alpha antagonist
Study: 19387646
Drug: Methotrexate (15–20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15–20 mg weekly for 3 months)
Study: 15480990
Drug: Recombinant coagulation
Normalized name: Recombinant coagulation factor IX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant coagulation factor VIIa (rFVIIa) 100 microg/kg, 8 doses
Study: 3356847
Drug: Four different
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four different SR theophylline formulations
Study: 28954098
Drug: Homologous platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous platelet gel
Study: 21333984
Drug: Micronized vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized vaginal P gel
Study: 21333984
Drug: Micronized P
Normalized name: Neo-Rx Micronized Powder for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized P capsule
Study: 17499653
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine and epinephrine (TLE) using sequential layered application
Study: 17499653
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine and epinephrine (TLE)
Study: 12585303
Drug: Pharmaceutical pricing
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical pricing after the policy change regarding patient out-of-pocket expenses.
Study: 9706049
Drug: Guar gum-based
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum-based diltiazem formulations
Study: 2712549
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day amantadine
Study: 2712549
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day amantadine
Study: 2712549
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day amantadine
Study: 29188864
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (1.3 g/kg/day)
Study: 29188864
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein intake (0.8 g/kg/day)
Study: 23488545
Drug: H1-receptor antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1-receptor antagonists
Study: 22123796
Drug: Nicotine therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine therapy sampling
Study: 19619700
Drug: Baseline use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline use of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)
Study: 11128341
Drug: Lisinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-20 mg once a day)
Study: 11128341
Drug: Nisoldipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20-40 mg once a day)
Study: 30345611
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of ranibizumab + pro re nata (prn)
Study: 30345611
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of ranibizumab + pro re nata (prn)
Study: 28691269
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/hour infusion)
Study: 28691269
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (same bolus and infusion rate as lidocaine)
Study: 27317550
Drug: Ametop™ (tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ametop™ (tetracaine 4%) gel applied to the skin of the lower back at least 20min before neuraxial block
Study: 21971356
Drug: High-titer neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer neutralizing antibodies (NAb) against two or more isolates (90% inhibitory dose > 500)
Study: 19857447
Drug: 3 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg IXIARO®
Study: 19857447
Drug: 6 μg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 μg IXIARO®
Study: 15095213
Drug: Azithromycin, 500
Normalized name: Azithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 500 mg per week for 8 weeks (R1)
Study: 15095213
Drug: Azithromycin, 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 1500 mg once at enrollment (R2)
Study: 15095213
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (R3)
Study: 11806304
Drug: H1 antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 antihistamines
Study: 9551842
Drug: Tiagabine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (10 mg three-times daily)
Study: 3051945
Drug: CG-120 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG-120 (3 or 4 g daily)
Study: 31588557
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of endocrine therapy
Study: 31588557
Drug: Residing in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residing in a higher income area; having progesterone receptor-positive tumors; receipt of chemotherapy, radiotherapy, and endocrine therapy
Study: 30945623
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg olanzapine (arm A; n=27)
Study: 30945623
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27)
Study: 30945623
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (reference arm C; n=27)
Study: 21631509
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy (oral hygiene instructions and subgingival scaling and root planing)
Study: 16476678
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (n = 24) for 15 days before FSH treatment
Study: 16476678
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (n = 25) for 15 days before FSH treatment
Study: 8321836
Drug: Felodipine extended-release
Normalized name: Felodipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended-release (ER) tablets 10 mg under fasting conditions
Study: 8321836
Drug: Felodipine extended-release
Normalized name: Felodipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended-release (ER) tablets 10 mg under nonfasting conditions
Study: 8321836
Drug: Felodipine extended-release
Normalized name: Felodipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended-release (ER) tablets 10 mg
Study: 8321836
Drug: Felodipine extended-release
Normalized name: Felodipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended-release (ER) tablets 10 mg with food
Study: 3963319
Drug: Oral physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physiological NaCl solution
Study: 3963319
Drug: Intramuscular physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular physiological NaCl solution
Study: 3963319
Drug: Parenteral premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral premedication
Study: 22519922
Drug: Bavisant 1
Normalized name: Bavisant
DrugBank: Bavisant (DB12299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavisant 1 mg/day
Study: 22519922
Drug: Bavisant 3
Normalized name: Bavisant
DrugBank: Bavisant (DB12299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavisant 3 mg/day
Study: 22519922
Drug: Bavisant 10
Normalized name: Bavisant
DrugBank: Bavisant (DB12299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavisant 10 mg/day
Study: 22519922
Drug: OROS Methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS Methylphenidate 54 mg/day
Study: 20511610
Drug: subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous methotrexate (scMTX)